Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Protocol ID
APG-115-US-002
Disease (Sub Disease)
Melanoma
Solid tumours
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Location
QLD
Sponsor
Ascentage Pharma Group Inc.
Collaborators
Merck Sharp & Dohme Corp.
Trial Status
Open
Sites
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Years and older
International registry ID's
NCT03611868
Back to Registry
Study Title A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Protocol ID APG-115-US-002
Disease (Sub Disease) Melanoma
Solid tumours
Diagnosis Stage New Diagnosis
Relapse/Refractory
Location QLD
Sponsor Ascentage Pharma Group Inc.
Collaborators Merck Sharp & Dohme Corp.
Links https://clinicaltrials.gov/ct2/show/NCT03611868
Trial Status Open
Trial Open Date 29/08/2018
Sites Queensland Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Years and older
International registry ID's NCT03611868